

24 **ABSTRACT**

25 **Objectives:** Our aims were to evaluate Systemic Lupus Erythematosus (SLE) disease activity
26 and SARS-CoV-2 specific immune responses after BNT162b2 vaccination.

27 **Methods:** In this prospective study, disease activity and clinical assessments were recorded
28 from the first dose of vaccine, until day 15 after the second dose in 126 SLE patients. SARS-
29 CoV-2 antibody responses were measured against wild-type spike antigen while serum-
30 neutralizing activity was assessed against the SARS-CoV-2 historical strain and variants of
31 concerns (VOCs). Vaccine-specific T-cell responses were quantified by Interferon (IFN)- γ
32 release assay after the second dose.

33 **Results:** BNT162b2 was well tolerated and no statistically significant variations of BILAG
34 and SLEDAI scores were observed throughout the study in SLE patients with active and
35 inactive disease at baseline. Mycophenolate Mofetil (MMF) and Methotrexate (MTX)
36 treatments were associated with drastically reduced BNT162b2 antibody-response ($\beta=-78$;
37 $p=0.007$, $\beta=-122$; $p<0.001$, respectively). Anti-spike antibody response was positively
38 associated with baseline total IgG serum levels, naïve B cell frequencies ($\beta=2$; $p=0.018$,
39 $\beta=2.5$; $p=0.003$) and SARS-CoV-2-specific T cell response ($r=0.462$; $p=0.003$). In
40 responders, serum neutralization activity decreased against VOCs bearing the E484K
41 mutation but remained detectable in a majority of patients.

42 **Conclusion:** MMF, MTX and poor baseline humoral immune status, particularly: low naïve
43 B cell frequencies, are independently associated with impaired BNT162b2 mRNA antibody
44 response, delineating SLE patients who might need adapted vaccine regimens and follow-up.

45 **KEYWORDS** SLE, BNT162b2 vaccine efficacy, SARS-CoV-2 neutralization, T cell
46 response, rheumatic and musculoskeletal diseases

47

48 **KEY MESSAGES**

49 **What is already known about this subject?**

- 50 • BNT162b2 efficacy and safety has been described in studies mixing different RMDs

51 **What does this study add?**

- 52 • No serious adverse effects, nor SLE flares have been documented after BNT162b2 in
53 SLE patients.
- 54 • Not only MMF and MTX, but also a poor humoral immune status at baseline impair
55 vaccine antibody response
- 56 • Albeit decreased, serum neutralizing activity against VOCs is conferred to vaccine-
57 responders.

58 **How might this impact on clinical practice or future developments?**

- 59 • These parameters could be helpful for physicians to delineate which patients should
60 have antibody measurement after full BNT162b2 vaccination and should be proposed
61 a third injection of BNT162b2 vaccine.

62

63

64 INTRODUCTION

65 Because of the tremendous paucity of data on the impact of rheumatic and musculoskeletal
66 diseases (RMD) and associated immune-modulatory treatments on Severe Acute Respiratory
67 Coronavirus-2 (SARS-CoV-2) vaccination efficacy, most of the recommendations are
68 currently based on expert opinions. Messenger RNA vaccination is a novel practice and its
69 tolerance, immunogenicity and efficacy are poorly documented in RMD. Consequently, rules
70 for vaccine against SARS-CoV2 vary according to country and over time [1,2]. Factors
71 affecting the anti-SARS-CoV-2 antibody response have been explored, but only after a first
72 dose or in studies mixing RMD [3,4]. Furthermore, the impact of treatments on the vaccine
73 response is often studied mixing different RMDs [5]. Importantly, Simon *et al.* recently
74 showed that inter-individual variations to vaccination were more related to the disease itself
75 rather than to concomitant treatments [3]. Additionally, most of these studies focused on
76 RMD treatments and not on the immunological status, which may also affect the antibody
77 response. Among RMDs, SLE could represent a peculiar challenge to vaccination against
78 SARS-CoV-2 [6]. The deregulation of type I interferon pathways associated with this
79 condition [7] might impact on vaccine antibody response [8]. SLE-associated impaired
80 lymphocyte functions might also impair vaccine efficacy [9,10]. Altogether, the risk of flares
81 induced by vaccines is highly dependent on the disease studied and the specific scores used to
82 measure this activity. It is therefore important to focus vaccine evaluation on homogeneous
83 groups of patients.

84 Compared with the general population, SLE patients do not seem to be at higher risk of
85 SARS-CoV-2 infections or severe COVID-19 [11–14], but this finding remains controversial
86 as others studies found that SLE patients may be at higher risk of hospitalization during their
87 COVID-19 course [15,16]. Increase of SLE disease activity has been previously reported
88 during COVID-19 [17,18] but the risk of SLE flares following vaccination does not appears to

89 be increased [18], although this point still requires confirmation through follow-up of SLE
90 patients evaluated at identical pre- and post-vaccination time points in a prospective study.
91 Finally, it remains unclear whether failures to induce antibody responses in patients under
92 immunomodulatory regimens such as abatacept, mycophenolate mofetil (MMF), CD-20
93 inhibitors, calcineurin inhibitors[5,19] are also associated, or not, with an absence of vaccine-
94 induced SARS-CoV-2-specific T cell responses. Here, we report post-vaccination disease
95 activity data in 126 SLE patients, prospectively followed during the completion of a two-dose
96 mRNA Pfizer/BioNTech (BNT162b2) vaccination regimen. SARS-CoV-2-specific humoral
97 and cellular responses were monitored against the SARS-CoV-2 historical strain, but also
98 against SARS-CoV-2 variants of concern (VOCs).

99 **METHODS**

100 **Patients**

101 The clinical study was conducted in the Internal Medicine Department 2, French National
102 Reference Center for SLE, Pitié-Salpêtrière Hospital, Paris, France. Eligible patients were 18
103 years or older, with a diagnosis of SLE according to the revised American College of
104 Rheumatology classification criteria [20]. Active lupus was defined with two scores: (i) at
105 least 1 British Isles Lupus Assessment Group (BILAG) B in any organ, (ii) SLE Disease
106 Activity Index (SLEDAI) 2K score > 4. Patients were vaccinated according to the French
107 recommendations for Covid-19 vaccination [2]. The study protocol was approved by the
108 Comité d’Ethique Sorbonne Université (CER-2021-011)

109 **Outcomes and follow-up**

110 Patients were vaccinated at baseline (1st dose) against SARS-CoV-2 with Pfizer/BioNTech
111 (BNT162b2) vaccine, and received the second dose at day (D)21-D28 unless contra-indicated.

112 Patients were evaluated at baseline and at D7-14, D21-D28, D42. They were asked to contact
113 their physician if they developed any symptoms in order to be promptly examined.

114 At each visit the following endpoints were assessed:

- 115 - Adverse events [21]
- 116 - SLE activity measured with SLEDAI 2K score [22,23] and BILAG score [24]
- 117 - SLE flares defined with the SELENA-SLEDAI flare index (SFI) [22,23] and BILAG 2004
118 score [24–26]
- 119 - SARS CoV-2 infection measured with anti-nucleocapsid antibodies
- 120 - Changes in serological activity (anti-dsDNA antibodies and C3), IFN α , anti-phospholipid
121 antibodies [27]
- 122 - Anti-spike antibodies
- 123 - B, T and NK cells quantification
- 124 - B lymphocyte subsets

125 **Patient and public involvement**

126 Patients were not involved in the design, or conduct, or reporting, or dissemination plans of
127 this research.

128 **Serological analysis**

129 SARS-CoV-2-specific IgG antibodies were measured as previously described [28]. Serum
130 samples were tested with the Maverick SARSCoV-2 Multi-Antigen Serology Panel (Genalyte
131 Inc., USA) according to the manufacturer's instructions. The panel is designed to detect
132 antibodies to five SARS-CoV-2 antigens: nucleocapsid, spike S1 Receptor Binding Domain
133 (RBD), spike S1S2, spike S2, and spike S1, within a multiplex format based on photonic ring
134 resonance technology. Briefly, 10 μ l of each serum sample was added to a sample well plate
135 array containing required diluents and buffers, and the plate and chip were loaded in the

136 instrument for chip equilibration with the diluent buffer to measure baseline resonance. The
137 serum sample was then charged over the chip to bind specific antibodies to antigens present
138 on the chip. The chip was then washed to remove low-affinity binders, and specific antibodies
139 were detected with anti-IgG secondary antibodies.

140 **Pseudoneutralization assay**

141 Lentiviral particles carrying the luciferase gene and pseudotyped with spikes of SARS-CoV-
142 2 historical strain or VOCs were produced by triple transfection of 293T cells as previously
143 described [28]. Serum dilutions were mixed and co-incubated with 300 Transducing Units of
144 pseudotyped lentiviral particles at room temperature for 30 min and then diluted in culture
145 medium [Dulbecco's modified Eagle's medium–GlutaMAX (Gibco) + 10% fetal calf serum
146 (Gibco) + 1% penicillin/streptomycin (Gibco)]. This mixture was then plated on tissue
147 culture–treated black 96-well plates (Costar) with 20,000 HEK 293T-hACE2 cells per well in
148 suspension. To prepare the suspension, cell flasks were washed with Dulbecco's PBS (DPBS)
149 twice (Gibco), and a single-cell suspension was made in DPBS + 0.1% EDTA (Promega) to
150 preserve integrity of hACE2 protein. After 48 hours, the medium was removed from each
151 well and bioluminescence was measured using a luciferase assay system (Promega) on an
152 EnSpire plate reader (PerkinElmer).

153 **B cell phenotyping**

154 B cell phenotyping was assessed on fresh whole blood. Briefly, 400µl of blood were washed
155 in PBS1X-RPMI 5% (Gibco) then transferred in tubes containing anti-CD45 V500, anti-
156 CD19 APC, anti-IgD FITC, anti-CD38 PerCPCy5.5, CD27 PE-Cy7, CD24 APC-H7, CD86
157 PE, CD3 BV421, CD14 BV421, CD21 BV421 lyophilized antibodies (BD Horizon™ Lyo
158 technology). This lyophilized version of the multicolor panel increases the reagent stability
159 and the assay performance. Cell staining was performed at room temperature for 15 minutes,

160 then cells were washed and fixed (BD Cell Fix®). Cells were acquired on a BD FACS Canto
161 II flow cytometer (BD Biosciences) and analyzed with FlowJo v10 software (FlowJo, LLC)
162 according to the gating strategy presented in Figure S1.

163 **SARS-CoV-2-specific T cell responses**

164 SARS-CoV-2-specific T cell responses were assessed in the clinical immunology laboratory
165 of Pitié-Salpêtrière Hospital by a whole blood Interferon-Gamma Release Assay (IGRA)
166 following manufacturer's instructions (Quantiferon SARS-CoV-2, Qiagen). This test uses two
167 Qiagen proprietary mixes of SARS-CoV-2 Spike protein (Ag.1 and Ag.2) selected to activate
168 both CD4 and CD8 T cells. Briefly venous blood samples were transferred into the
169 Quantiferon® tubes containing Spike peptides as well as positive and negative controls.
170 Whole blood was incubated at 37°C for 16-24 hours and centrifuged to separate plasma. IFN-
171 γ (IU/ml) was measured in these plasma samples using QuantiFERON Human IFN- γ SARS-
172 CoV-2 ELISA kit (Qiagen) on Dynex DS2® analyzer (Qiagen).

173 **Statistical analysis**

174 Baseline characteristics are reported with descriptive statistics. Linear regression models were
175 used to assess the association between clinical and biological characteristics and the titer of
176 IgG anti-RBD at day 42 in unadjusted and multivariable analysis. We considered potential
177 confounders known or suspected to be associated with vaccine response such as demographic
178 features (age, sex), activity of SLE, concomitant immune modulatory treatments and data
179 from T, B and NK cells phenotyping. The beta coefficient is the degree of change in the
180 outcome variable for every 1-unit of change in the predictor variable. If the beta coefficient is
181 not statistically significant (*i.e.*, the p-value is not significant), the variable does not
182 significantly predict the outcome. If the beta coefficient is significant, examine the sign of the
183 beta. If the beta coefficient is positive, the interpretation is that for every 1-unit increase in

184 the predictor variable, the outcome variable will increase by the beta coefficient value. If the
185 beta coefficient is negative, the interpretation is that for every 1-unit increase in the predictor
186 variable, the outcome variable will decrease by the beta coefficient value. For example, if the
187 beta coefficient is 0.80 and statistically significant, then for each 1-unit increase in the
188 predictor variable, the outcome variable will increase by 0.80 units. Paired t-tests were used to
189 detect differences in activity scores and biological data over time. As we excluded the 10
190 patients for whom follow-up was incomplete, we did not have to perform any imputation for
191 missing data. Nonparametric test were used as Mann-Whitney U test to compare two
192 independent groups, Wilcoxon test to compare paired values and Pearson coefficient to
193 calculate correlation. Significant P values are indicated as described below: * $p < 0.05$;
194 ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$. Statistical analysis was performed using R software
195 (version 4.1.0) and GraphPad Prism software, V6 (GraphPad, San Diego).

196 **RESULTS**

197 **Demographic and disease characteristics**

198 Vaccination against SARS-CoV-2 with Pfizer/BioNTech vaccine was proposed by their SLE
199 referring physician to 180 patients with SLE; 127 (70.5 %) immediately accepted, 35 (19.4%)
200 patients refused and 18 (10.0%) eventually accepted upon reflection, 9 of them were
201 vaccinated in another center (Figure 1). A total of 136 SLE patients were enrolled and
202 received one first dose; 3 patients received only one dose: either because they developed
203 COVID-19 within 10 days after the first dose ($n=2$), or because COVID-19 had been
204 contracted three months before the 1st dose ($n=1$). Among the 133 SLE patients who received
205 2 doses, 126 (92.6%) completed all the visits and were included in the final analysis. Baseline
206 clinical characteristics of these 126 patients are summarized in Table 1. Treatments received
207 from D1 to D42 were distributed as follows: hydroxychloroquine ($n = 106$; 84.1%; median
208 daily dose : 400 mg), prednisone ($n = 70$; 55.5%) with 57 patients (45.2%) receiving less than

209 10mg daily (median daily dose : 5 mg) and 13 (10.3%) more than 10 mg daily (median daily
 210 dose : 19 mg), methotrexate (n = 20 ; 15.9% ; median weekly dose 15 mg) ; mycophenolate
 211 mofetil (n = 24 ; 19.0%; median daily dose = 2000 mg), azathioprine (n = 5 ; 4.0% ; median
 212 daily dose : 100 mg) and belimumab (n = 15 ; 11.9%), of whom 7 had intra-venous and 8
 213 subcutaneous injections, respectively.

214 **Table 1. Demographics and clinico-biological features of SLE patients**

	N = 126
Female sex	114 (90.5%)
Age, years	46.6 (33.9, 58.7)
Time from SLE onset, months	14.1 (7.2, 23.1)
Time from last flare, months	2.4 (0.5, 6.2)
SLEDAI 2K	2.0 (0.0, 4.0)
SLEDAI 2K > 4	24 (19.0%)
At least one BILAG score ≥ B	20 (16.7%)
Hydroxychloroquine blood dosage, µg/L	855.5 (641.0, 1,123.0)
Low complement C3 (< 0.7g/L)	22 (17.5%)
Increased dsDNA binding (> 30 IU/mL)	63 (50.0%)
Detectable interferon alpha (> 2 IU/mL)	17 (14.8%)
Hydroxychloroquine	106 (84.1%)
No corticosteroids	56 (44.4%)
Corticosteroids ≤10mg/day	57 (45.2%)
Corticosteroids >10mg/day	13 (10.3%)
Belimumab (Intravenous, n=7, Subcutaneous, n=8)	15 (11.9%)
Mycophenolate mofetil	24 (19.0%)
Azathioprine	5 (4.0%)
Methotrexate	20 (15.9%)

Qualitative variables are presented as n (%); Quantitative variables are presented as median (Interquartile range); dsDNA: double stranded DNA; SLEDAI: SLE Disease activity score; BILAG: British Isles Lupus Assessment Group

215

216 **Adverse BNT162b2 vaccine-associated events in SLE patients**

217 No related serious adverse events (SAE), no grade 4 reactions, and no withdrawals due to
 218 related adverse events (AEs) were observed (Figure S2 and Table S1). Local reactions,
 219 predominantly pain at the injection site, were mild to moderate (grade 1 and 2).

220 **BNT162b2 vaccine effect on SLE disease activity**

221 At baseline, 29 (23.0%) and 20 (16.7%) patients had active SLE according to SLEDAI
222 (SLEDAI 2K > 4) and to BILAG (≥ 1 BILAG B), respectively. Within 42 days following
223 vaccination (Figure 2A), mild disease flares were observed in 3 patients following
224 vaccination, with a mucocutaneous BILAG score going from C to A in 1 individual, a
225 musculoskeletal BILAG going from C to B in 1 individual and from D to C for 1 another
226 vaccinated patient. In return, 9 patients (5 active and 4 inactive) clinically improved following
227 vaccination with a musculoskeletal BILAG going from B to C for 4 patients and from C to D
228 for 3 patients, a mucocutaneous BILAG going from A to C for 1 patient and a renal BILAG
229 going from A to B for 1 patient. No statistically significant variation of SLEDAI score was
230 observed throughout the study for active and inactive SLE patients according to initial
231 SLEDAI score (SLEDAI 2K score ≤ 4 at day 1: mean[sd]; 1.2[1.4] day 1; 1.3[1.2] day 14;
232 1.0[1.2] day 28; 1.3[1.4] day 42, ns; SLEDAI score >4 at day 1: 11[5.1] day 1; 10.1[4.9] day
233 14; 10.0[5.3] day 28; 9.9[5.3] day 42, ns; Figure 2B). Altogether, vaccination is not
234 preferentially associated with exacerbation of SLE symptoms, than with clinical
235 improvement. When observed, variations of BILAG and SLEDAI scores were not
236 preferentially observed in either active or inactive SLE patients at baseline.

237 **Effect of treatments and baseline immune status on the immunogenicity of the** 238 **BNT162b2 vaccine in SLE**

239 Higher total serum IgG levels measured at baseline were associated with better seropositivity
240 rates ($\beta = 2.0$; 95% CI: 0.34, 3.6; $p = 0.018$), while MMF and MTX uses were associated with
241 lower anti-spike antibody production ($\beta = -78$; 95% CI: -133, -22; $p = 0.007$ and $\beta = -122$;
242 95% CI: -184, -61; $p < 0.001$, respectively) measured 14.7 days on average after the second
243 injection (standard deviation 1.9 days). Total lymphocyte counts and IFN α levels at baseline

244 were not significantly associated with seropositivity rates (Table 2). Hydroxychloroquine,
 245 steroids (either high or low dose) or belimumab use during the 42 days following vaccination
 246 did not impact anti-spike antibody production. Of note, SLE activity was not correlated with
 247 anti-spike antibody response, regardless of the score used to measure disease activity (see
 248 Table 2 and Table S2 with BILAG and SLEDAI, respectively).

249

250 **Table 2. Baseline predictors of day 42 anti-SARS-CoV-2 RBD IgG titers according to**
 251 **linear regression model.** SLE activity is measured with BILAG score.

	β	95% CI	p-value
Age, years	-0.61	-2.0, 0.75	0.4
Male sex	-62	-127, 3.7	0.064
At least one BILAG score \geq B	-45	-106, 17	0.2
C3, g/L	35	-77, 147	0.5
dsDNA antibodies, IU/mL	0.04	-0.06, 0.13	0.4
Detectable IFN alpha	-3.4	-7.4, 0.58	0.093
Total serum IgA, g/L	1.8	-12, 16	0.8
Total serum IgG, g/L	2.0	0.34, 3.6	0.018
Total serum IgM, g/L	12	-1.0, 24	0.071
Lymphocytes count, G/L	6.6	-31, 44	0.7
Corticosteroids low	-20	-66, 26	0.4
Corticosteroids high	-50	-127, 28	0.2
Hydroxychloroquine	-27	-85, 31	0.4
Azathioprine	-118	-242, 6.5	0.063
Belimumab	-18	-90, 54	0.6
Mycophenolate mofetil	-78	-133, -22	0.007
Methotrexate	-122	-184, -61	<0.001
Other immunosuppressor	62	-32, 156	0.2

β : see Material and methods; BILAG: British Isles Lupus Assessment Group; CI = Confidence Interval; dsDNA: double stranded DNA; IFN: Interferon; RBD: Receptor Binding Domain

252

253 Since IgG levels but not total lymphocyte counts were significantly associated with the
 254 antibody response, we next studied the effect of lymphocyte sub-populations counts at
 255 baseline (Table 3).

256 **Table 3. Baseline B, T and NK cells counts predictors of day 42 anti-SARS-CoV-2 RBD**
 257 **IgG titers according to linear regression model.**

	β	95% CI	p-value
B lymphocytes count, G/L	0.38	0.13, 0.62	0.003
NK lymphocytes count, G/L	0.21	-0.37, 0.80	0.5
CD4+T lymphocytes count, G/L	0.01	-0.09, 0.11	0.9
CD8+T lymphocytes, G/L	-0.01	-0.16, 0.13	0.8

β : see Material and methods; CI=Confidence Interval

258 We found that B lymphocyte counts were the sole lymphocyte population associated with
 259 anti-spike antibody response ($\beta = 0.38$; 95% CI: 0.13, 0.62; $p=0.003$). We further
 260 characterized the effect of B lymphocyte subsets at baseline. Treatments modifying B cell
 261 subpopulations were adjusted in this analysis (Table 4). Strikingly, naive B lymphocytes
 262 frequency at baseline was positively associated with anti-spike antibody response at D42 ($\beta =$
 263 2.5 ; 95% CI; 0.87, 4.0; $p=0.003$; Table 4).

264 **Table 4. Baseline B cell predictors of day 42 anti-SARS-CoV-2 RBD IgG titers according**
 265 **to linear regression model**

	β	95% CI	p-value
Corticosteroids ≤ 10 mg/day	-42	-93, 9.0	0.10
Corticosteroids > 10 mg/day	-135	-269	0.007
Hydroxychloroquine	-34	-110, 43	0.4
Azathioprine	-71	-233, 92	0.4
Belimumab	9.6	-105, 125	0.9
Mycophenolate mofetil	-146	-292	<0.001
Methotrexate	-121	-243	0.004
Other immunosuppressor	203	5.6, 401	0.044
Marginal zone B lymphocytes, Day 1 (%)	-0.22	-2.7, 2.3	0.9
Autoreactive B lymphocytes, Day 1 (%)	-1.5	-4.3, 1.3	0.3
Naive B Lymphocytes, Day 1 (%)	2.5	0.87, 4.0	0.003
Double negative B lymphocytes, Day 1 (%)	3.8	-2.2, 9.9	0.2
Memory B lymphocytes, Day 1 (%)	-0.57	-2.3, 1.2	0.5

β : see Material and methods; CI=Confidence Interval; Autoreactive B cells (CD21^{low}CD38^{low}); Double Negative B cells (CD27-IgD⁻); Marginal Zone B cells (CD27+IgD⁺); Memory B cells (CD27+IgD⁻); Naïve B cells (CD27-IgD⁺). B cell subsets frequencies are measured in total B cells.

267 **Effect of treatments on BNT162b2-induced neutralization responses**

268 We next analyzed whether vaccine-induced antibody-responses may be protective by
269 evaluating serum-neutralizing activity. As expected, we confirm a strong correlation between
270 anti-RBD antibody levels and neutralization titers (SARS-CoV-2 D614G $r=0.82$, $p<0.0001$;
271 Figure 3A). Consequently, parameters listed above influencing seroconversion also influenced
272 neutralization activity (Table S3). MMF and MTX in particular have a negative impact on
273 induction of neutralizing activity ($\beta = -1.1$; 95% CI: -1.9, -0.34; $p = 0.005$ and $\beta = -1.9$; 95%
274 CI: -2.7; -1.1; $p <0.001$, respectively, Table S3). While a majority of MMF/MTX-treated
275 patients still harbored detectable neutralizing activity (65% (15/23) MMF-treated patients,
276 68% (13/19) MTX-treated patients vs 96% (81/84) patients without MMF or MTX), their
277 serum neutralizing activity drastically dropped compared to patients receiving other
278 treatments (Inhibitory Dilution 50 (ID50) D614G median[*min-max*]; 111.2[30-18910] in
279 MMF-treated patients vs 90.4[30-5527] in MTX-treated patients and 684.6[30-12061] in other
280 patients; $p<0.05$; Figure 3B).

281 **Effect of baseline immune status on BNT162b2-induced neutralization responses**

282 Consistent with serological studies, naïve B cell decrease at baseline was negatively
283 associated with serum D42 neutralizing activity ($\beta = 0.04$; 95% CI: 0.01, 0.07; $p = 0.006$;
284 Table S4). As shown in Figure 3C, patients with a low naïve B cell compartment (<42% of B
285 cells) developed a lower neutralizing activity than patients with normal or high naïve B cell
286 subset frequencies (229.2[30-2510] in low naïve B cell patients vs 468.3[30-5421]; $p<0.05$;
287 Figure 3C). To more accurately evaluate the effect of naïve B cells on neutralizing antibody-
288 response, we divided SLE patients in 4 groups according to their naïve baseline B cell counts
289 (median[*min-max*] naïve B cell counts/ μl : 9[0.01-23.2]; 41[27.2-50.9]; 68.1[57.2-98.7];
290 133.8[110.1-160.2] in quartiles 1, 2, 3 and 4, respectively; Figure 3D). We confirm that naïve

291 B cell counts are positively associated with vaccine-induced neutralizing antibody-responses
292 (ID50 D614G 93.4[30-246.5] vs 340.1[30-1632] in quartiles 1 and 2, respectively; $p < 0.05$, vs
293 315.2[30-721.1] in quartile 3 $p < 0.05$; vs 679.9[60.4-2510] in quartile 4; $p < 0.001$; Figure 3D).

294 These data therefore underline the importance of interrogating initial B cell status as well as
295 immunosuppressive treatments to predict vaccine response.

296 **Broad neutralizing activity against VOCs in BNT162b2 vaccine responders**

297 The Pfizer/BioNTech vaccine was designed to target the Wuhan isolate described by the end
298 of 2019. However, emerging variants, with enhanced infectivity and the ability to escape
299 immune control, rapidly became dominant. Concerns have been raised as to whether
300 Pfizer/BioNTech vaccine will be effective against these emerging variants, particularly in
301 vaccinated individuals receiving immunosuppressive drugs. We therefore measured
302 neutralizing activities in the last 46 serum samples longitudinally collected against 4 major
303 SARS-CoV-2 lineages: B.1.1.7 (originating in United Kingdom), B.1.351 (described in South
304 Africa), B.1.1.28 (reported in Brazil) and B.1.617 (emerged in India). Consistent with
305 previous studies [29,30], we found that vaccine-induced IgG antibodies efficiently cross-
306 neutralize variants B.1.1.7 (Inhibitory Dilution 50 (ID50) median[*min-max*]; D614G 1453[30-
307 18910] and B.1.1.7 514.5 [30-12625], ns, Figure 3E). It is noteworthy that serum
308 neutralization activity decreased with lineages bearing the E484K mutation in the RBD (ID50
309 B.1.617.1 341.1[30-3996], $p < 0.001$; B.1.617.2 379.3[30-4982], $p < 0.001$; B.1.617.3 317.9[30-
310 3604], $p < 0.01$; B.1.1.28 302.3[30-5757] and B.1.351 88.1[30-2389]; $p < 0.0001$; Figure 3E),
311 but remained detectable in a majority of patients (82% for B.1.1.7; 73% for B.1.617.1; 76%
312 for B.1.617.2; 71% for B.1.617.3; 73% for B.1.1.28; 60% for B.1.351; Figure 3F). Among
313 patients with neutralizing antibody activity against D614G strain, 100% (37/37) of patients
314 also efficiently neutralized B.1.1.7 strain, 89% (33/37) B.1.617.1 variant, 92% (34/37)

315 B.1.617.2 variant, 87% (32/37) B.1.1.28 variant, 89% (33/37) B.1.1.28 variant and 60% of
316 patients (27/37) had detectable neutralizing activity against B.1.351.

317 Altogether these results demonstrated that vaccinated-SLE harbored decreased neutralizing
318 activity against VOCs, as previously described in vaccinated healthy donors [31,32].

319 **SARS-CoV-2-specific T cell responses induced by the BNT162b2 vaccine in SLE**

320 Beyond antibodies, T-cell immunity is required to confer optimal immune protection. In order
321 to gain insight into the specific SARS-CoV-2 T cell response after vaccination in SLE
322 patients, we evaluated IFN gamma secretion levels after specific T cell stimulation at day 15
323 after vaccination. While SARS-CoV-2-specific T cell responses were detected in 57%
324 (17/30) of patients who had neutralizing antibody titers, cellular responses were only detected
325 in 10% (1/10) of patients who had non-neutralizing antibody titers ($p < 0.05$; Figure 4A).
326 Interestingly, SARS-CoV-2-specific T cell responses were nevertheless detected in 2 out of 6
327 patients with very low levels of neutralizing activity in their serum (ID50 below 100 for
328 D614G strain). Overall the strength of neutralizing antibody-response correlates with IFN- γ
329 production by SARS-CoV-2 specific T cells (Antigen 1, $r = 0.462$, $p = 0.003$; Antigen 2
330 $r = 0.424$, $p = 0.007$, Figure 4B).

331 **DISCUSSION**

332 Here, we report BNT162b2 antibody response measured both with anti-RBD antibody levels
333 and neutralization activity in a cohort of 126 SLE french patients, with both active and
334 inactive disease. To our knowledge, this is the first evaluation of BNT162b2-induced T cell
335 and neutralization responses against VOCs in a cohort of SLE patients.

336 Global acceptance of BNT162b2 vaccine was 80.5%, in line with previous studies [33]. Most
337 SLE patients were followed for a long time before vaccination in our center and vaccine was
338 proposed by their treating physician. Interestingly, 18 (10%) patients who first refused

339 vaccination, finally agreed to be vaccinated after a reflection time, a finding that is often
340 lacking in Covid-19 vaccine acceptance studies. Tolerance of BNT162b2 vaccine was also
341 good with a majority of local reactions and few systemic reactions.

342 SLE activity at time of vaccination, assessed either with the BILAG or the SLEDAI scores,
343 neither reduced vaccine efficacy, nor increased the risk of subsequent SLE flares or vaccine
344 side-effects. Consistent with this finding, previous meta-analysis of seasonal influenza and
345 pneumococcal vaccinations in SLE demonstrated that immunization had no significant effect
346 on the SLE activity measured with SLEDAI score [34]. Our results support the
347 recommendation not to defer mRNA vaccination in active SLE patients [1]. One should note,
348 however, that active SLE patients would subsequently receive treatments that could blunt
349 BNT162b2 antibody-response. Indeed, MMF profoundly lowers BNT162b2 antibody-
350 response as previously reported in transplant recipients [35] and RMDs patients [5]. MTX, a
351 drug which is widely used for SLE, decreases Covid-vaccine antibody-response in a similar
352 extent to MMF. Our results confirm recent studies [5,36] showing that MTX hampers
353 immunogenicity to BNT162b2 mRNA Covid-19 vaccine in immune-mediated inflammatory
354 diseases. However, since these two studies mixed different RMDs, the impact of these two
355 drugs on BNT162b2 mRNA antibody response was assessed without adjusting with specific
356 SLE parameters that could also affect BNT162b2 antibody-response (disease activity, IFN α
357 levels). Reduced humoral responses to both seasonal influenza and pneumococcal vaccines
358 with MTX in RA patients have been previously reported [37,38] while transitory MTX
359 discontinuation improves the immunogenicity of seasonal influenza vaccination in RA
360 patients [39–42]. Based on this RCT, the ACR recommended withholding MTX one week
361 before each of the COVID-19 vaccine doses [1], but the evidence supporting this
362 recommendation is unclear and was counterbalanced by the potential for RA flare associated

363 with withholding MTX for a too long period, a recommendation that could not be
364 extrapolated to SLE.

365 By contrast, neither hydroxychloroquine nor anti-BAFF belimumab did affect vaccine
366 antibody-response. High-dose steroids were not associated either with a lower vaccine-
367 induced antibody-response. The median prednisone daily high-dose was 19 mg in our study, a
368 threshold that is lower than the one used for transplant recipient patients [43]. There is still
369 controversy regarding the effect of steroids on SARS-CoV-2 vaccine efficacy, in particular
370 whether a daily dose prednisone threshold above which antibody response might be blunted
371 could be defined[1]. As a consequence, there is currently no expert panel recommendation to
372 delay or not Covid vaccination in RMD patients receiving glucocorticoids at a prednisone-
373 equivalent dose of ≥ 20 mg per day [1]. Optimal antibody responses seem to be elicited in
374 RMDs patients on glucocorticoid monotherapy [44], although the daily prednisone dose was
375 not reported in the latter study. Our data suggest that SLE patients with a daily dose of
376 prednisone close to 20 mg should properly respond to BNT162b2 vaccine.

377 Elevated IFN-alpha serum levels were not associated with impaired BNT162b2 antibody-
378 response, an observation in line with the lack of influence of SLE activity on vaccine efficacy.
379 By contrast, elevated baseline total serum IgG levels were associated with a better antibody
380 response. This association remains significant ($p=0.018$) when the analysis is adjusted for
381 immunosuppressive drugs that could decrease IgG levels. For Chronic Lymphocytic
382 Leukemia (CLL) patients, higher serum immunoglobulin levels at time of BNT162b2 mRNA
383 vaccination were independently associated with a better response rate (IgG levels ≥ 550
384 mg/dL (OR 3.70, 95% CI 1.08-12.66)[45]. IgM levels were also an independently associated
385 with serologic response (IgM ≥ 40 mg/dL (OR 2.92, 95% CI 1.21-7.02) in these patients. The
386 influence of baseline IgG and IgM levels on COVID vaccine antibody-response have never
387 been reported before in RMD and might be considered in future studies.

388 Our data also underline the importance of interrogating initial B cell compartments as
389 correlates of predicted vaccine response. A marked decrease of naive B cells is known to be
390 characteristic of SLE and not only the result of immunosuppressive drugs [46,47]. Here we
391 observed a strong correlation of naive B cell loss with poor vaccine antibody-response, which
392 likely points the role of naive B cells as a source of spike reactive-B cells. In recent studies
393 extensive screening of pre-pandemic naive B cell repertoires revealed the presence of SARS-
394 CoV-2-neutralizing antibody precursors. This subset of germline antibodies bound SARS-
395 CoV-2 ACE2 receptor binding domain (RBD), albeit weakly, and may be engaged upon
396 vaccine exposure to generate germinal centers and then follow affinity maturation process
397 [48,49]. Indeed, Rincon-Arevalo *et al.* observed a significant difference in the frequency of
398 SARS-CoV-2 RBD-specific naïve B cells between BNT162b2-responders and non-
399 responders [50]. Reduced naive B cell pool in SLE would thus readily impact precursor
400 frequency available to encounter the antigen, therefore impairing vaccine efficiency. Future
401 vaccination strategies in SLE should consider naive B cells as an essential biomarker to define
402 individuals at high risk of sub-optimal response that might benefit from reinforced vaccine
403 regimens. It will remain to define in future studies whether patients eventually seroconverting
404 after a third dose would have had readily detectable T cell responses after the second dose.
405 Finally, much larger studies will be necessary to determine whether BNT162b2-induced T
406 cell responses are solely sufficient to prevent at least from severe forms of the COVID-19 in
407 patients.

408 Our study has some limitations. It is surprising to note that SARS-CoV-2-specific T cell
409 responses were detected in only 57% of patients who had neutralizing antibody titers. This
410 observation questions the sensitivity of the QTF assay used in our study and another [51].
411 Future studies should include other assays such T cell ELISPOT[52] to confirm this
412 observation and whether low T cell responses would be more likely associated with SLE,

413 compared to other RMDs and to healthy controls. Moreover, QTF assay was performed 15
414 days after the second dose, a timing that may be too short to optimally detect SARS-CoV-2
415 specific T cell response. Longitudinal studies are thus required to determine whether SLE
416 patients develop a delayed cellular immune response. Unlike previous authors [3–5], we did
417 not use antibody-response positivity thresholds. There are, however, no studies showing that
418 these thresholds give RMD patients real protection against the risk of subsequent infection
419 with SARS-CoV-2. It is not yet clear as to what immunogenicity parameter is predictive of
420 vaccine-induced protection. Additionally, these thresholds vary according to the assays used
421 and the variants studied, their clinical relevance is therefore questionable. To address this
422 issue, Khoury *et al.* [53] recently analyzed the relationship between *in vitro* neutralization
423 levels and the observed protection from SARS-CoV-2 infection using data from seven current
424 vaccines and from convalescent cohorts. These authors found that despite expected
425 inconsistencies between studies, comparison of normalized neutralization levels and vaccine
426 efficacy demonstrates a remarkably strong non-linear relationship between mean
427 neutralization level and the reported protection across different vaccines (Spearman $r=0.905$;
428 $P=0.0046$). In this setting, the strong correlation we observed between RBD-antibody levels
429 and the neutralizing activity is reassuring about the usefulness of serology in clinical practice.
430 In our survey, only one patient out of 126 presented high IgG anti-RBD levels and low
431 neutralizing activity (Figure 3A). Antibody response was assessed 14 days after the second
432 injection. We cannot rule out the hypothesis that a higher antibody response would have been
433 observed later [44]. Of note, Polack *et al.* measured antibody responses as soon as 7 days after
434 second injection [21] and were able to link BNT162b2 efficacy to prevention of SARS-CoV-2
435 infections in healthy individuals. Last, this SLE cohort did not comprise rituximab-treated
436 patients, in whom antibody responses are abrogated [54]. Rituximab is not approved for SLE
437 although used in clinical practice.

438 Despite its limitations, this study provides evidence that in SLE, use of MMF or MTX is
439 associated with reduced vaccine efficacy. We also show that low baseline IgG levels and a
440 reduced pool of naive B cells are predictive of impaired vaccination-induced neutralizing
441 activity against SARS-CoV-2. These parameters could be helpful for physicians to delineate
442 which patients should have antibody measurement after full BNT162b2 vaccination and
443 should be proposed a third injection of BNT162b2 vaccine.

444 **ACKNOWLEDGMENTS**

445 The authors wish to thank the patients who agreed to participate in this study, nurses from the
446 Internal Medicine Department of Institut E3M (Assistance Publique Hôpitaux de Paris (AP-
447 HP), Hôpital Pitié-Salpêtrière, 75013 Paris, France) who participated in this study, all
448 members from the Immunology Department, (Assistance Publique Hôpitaux de Paris (AP-
449 HP), Hôpital Pitié-Salpêtrière, 75013 Paris, France), who performed Quantiferon analysis and
450 B-cell phenotyping, Laura Wakselman from clinical research unit (URC) of Pitié-Salpêtrière
451 Hospital for help with regulatory and ethical issues.

452 **COMPETING INTERESTS**

453 Z.A. has received research grants from Amgen, AstraZeneca, GSK and Roche, fees for
454 consultancy from AstraZeneca, GSK and Kezar. M.M. received consulting fees from
455 Genalyte Inc. 3 years ago. Other authors declare that they have no competing interests.

456 **CONTRIBUTORSHIP**

457 Q.M, A.M, R.L, F.C-A, J.H, M.P, L.B, Z.A recruited patients. Q.M, P.B, C.H, F.P, P.G
458 collected demographic and clinico-biological data. M.M, D.S, P.G prepared the specimens.
459 M.M, Q.M, F.A, D.S designed and performed experiments. Q.M, D.S, F.A, M.M, S.A, S.M
460 analyzed data. Q.M, D.S prepared the figures. Q.M, D.S, G.G, Z.A wrote the manuscript.
461 Q.M, D.S, F.A, M.M, G.G, Z.A designed the study and reviewed the manuscript.

462 **DATA SHARING STATEMENT**

463 All data are available in the manuscript or the supplementary materials.

464 **ETHICAL APPROVAL INFORMATION**

465 The study protocol was approved by the Comité d’Ethique Sorbonne Université (CER-2021-
466 011)

467 **FUNDING**

468 The study was supported by the Agence Nationale de la Recherche (ANR Flash COVID19
469 program, MUCOVID, PI: D.S.), and by the SARS-CoV-2 Program of the Faculty of Medicine
470 from Sorbonne University ICOViD programs, PI: G.G.).

471

472 **REFERENCES**

- 473 1 Curtis JR, Johnson SR, Anthony DD, *et al.* American College of Rheumatology
474 Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal
475 Diseases: Version 1. *Arthritis & Rheumatology* 2021;**n/a**. doi:10.1002/art.41734
- 476 2 Haut Conseil de la santé publique. Avis complémentaire à l’avis du 14 janvier relatif
477 aux mesures de contrôle et de prévention de la diffusion des nouveaux variants du SARS-
478 CoV-2. 2021.
- 479 3 Simon D, Tascilar K, Fagni F, *et al.* SARS-CoV-2 vaccination responses in untreated,
480 conventionally treated and anticytokine-treated patients with immune-mediated inflammatory
481 diseases. *Ann Rheum Dis* Published Online First: 6 May 2021. doi:10.1136/annrheumdis-
482 2021-220461
- 483 4 Boyarsky BJ, Ruddy JA, Connolly CM, *et al.* Antibody response to a single dose of
484 SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. *Ann*
485 *Rheum Dis* Published Online First: 23 March 2021. doi:10.1136/annrheumdis-2021-220289
- 486 5 Furer V, Eviatar T, Zisman D, *et al.* Immunogenicity and safety of the BNT162b2
487 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic
488 diseases and in the general population: a multicentre study. *Ann Rheum Dis* Published Online
489 First: 14 June 2021. doi:10.1136/annrheumdis-2021-220647
- 490 6 Tang W, Askanase AD, Khalili L, *et al.* SARS-CoV-2 vaccines in patients with SLE.
491 *Lupus Sci Med* 2021;**8**. doi:10.1136/lupus-2021-000479
- 492 7 Postal M, Vivaldo JF, Fernandez-Ruiz R, *et al.* Type I interferon in the pathogenesis
493 of systemic lupus erythematosus. *Curr Opin Immunol* 2020;**67**:87–94.
494 doi:10.1016/j.coi.2020.10.014

- 495 8 Björk A, Da Silva Rodrigues R, Richardsdotter Andersson E, *et al.* Interferon
496 activation status underlies higher antibody response to viral antigens in patients with systemic
497 lupus erythematosus receiving no or light treatment. *Rheumatology (Oxford)* Published Online
498 First: 2 October 2020. doi:10.1093/rheumatology/keaa611
- 499 9 Chen P-M, Tsokos GC. T Cell Abnormalities in the Pathogenesis of Systemic Lupus
500 Erythematosus: an Update. *Curr Rheumatol Rep* 2021;**23**:12. doi:10.1007/s11926-020-00978-
501 5
- 502 10 Mathian A, Devilliers H, Krivine A, *et al.* Factors influencing the efficacy of two
503 injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus
504 erythematosus. *Arthritis Rheum* 2011;**63**:3502–11. doi:10.1002/art.30576
- 505 11 Mathian A, Mahevas M, Rohmer J, *et al.* Clinical course of coronavirus disease 2019
506 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term
507 treatment with hydroxychloroquine. *Ann Rheum Dis* 2020;**79**:837–9.
508 doi:10.1136/annrheumdis-2020-217566
- 509 12 Ramirez GA, Gerosa M, Beretta L, *et al.* COVID-19 in systemic lupus erythematosus:
510 Data from a survey on 417 patients. *Semin Arthritis Rheum* 2020;**50**:1150–7.
511 doi:10.1016/j.semarthrit.2020.06.012
- 512 13 Favalli EG, Gerosa M, Murgu A, *et al.* Are patients with systemic lupus
513 erythematosus at increased risk for COVID-19? *Ann Rheum Dis* 2021;**80**:e25.
514 doi:10.1136/annrheumdis-2020-217787
- 515 14 Gartshteyn Y, Askanase AD, Schmidt NM, *et al.* COVID-19 and systemic lupus
516 erythematosus: a case series. *Lancet Rheumatol* 2020;**2**:e452–4. doi:10.1016/S2665-
517 9913(20)30161-2

- 518 15 Fernandez-Ruiz R, Masson M, Kim MY, *et al.* Leveraging the United States Epicenter
519 to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. *Arthritis*
520 *Rheumatol* 2020;**72**:1971–80. doi:10.1002/art.41450
- 521 16 Gianfrancesco M, Hyrich KL, Al-Adely S, *et al.* Characteristics associated with
522 hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19
523 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2020;**79**:859–66.
524 doi:10.1136/annrheumdis-2020-217871
- 525 17 Raghavan S, Gonakoti S, Asemota IR, *et al.* A Case of Systemic Lupus Erythematosus
526 Flare Triggered by Severe Coronavirus Disease 2019. *J Clin Rheumatol* 2020;**26**:234–5.
527 doi:10.1097/RHU.0000000000001531
- 528 18 Kondo Y, Kaneko Y, Oshige T, *et al.* Exacerbation of immune thrombocytopenia
529 triggered by COVID-19 in patients with systemic lupus erythematosus. *Ann Rheum Dis*
530 Published Online First: 5 August 2020. doi:10.1136/annrheumdis-2020-218157
- 531 19 Rozen-Zvi B, Yahav D, Agur T, *et al.* Antibody response to SARS-CoV-2 mRNA
532 vaccine among kidney transplant recipients: a prospective cohort study. *Clin Microbiol Infect*
533 Published Online First: 3 May 2021. doi:10.1016/j.cmi.2021.04.028
- 534 20 Hochberg MC. Updating the American College of Rheumatology revised criteria for
535 the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;**40**:1725.
536 doi:10.1002/art.1780400928
- 537 21 Polack FP, Thomas SJ, Kitchin N, *et al.* Safety and Efficacy of the BNT162b2 mRNA
538 Covid-19 Vaccine. *N Engl J Med* 2020;**383**:2603–15. doi:10.1056/NEJMoa2034577
- 539 22 Buyon JP, Petri MA, Kim MY, *et al.* The effect of combined estrogen and
540 progesterone hormone replacement therapy on disease activity in systemic lupus

- 541 erythematosus: a randomized trial. *Ann Intern Med* 2005;**142**:953–62. doi:10.7326/0003-
542 4819-142-12_part_1-200506210-00004
- 543 23 Petri M, Kim MY, Kalunian KC, *et al.* Combined oral contraceptives in women with
544 systemic lupus erythematosus. *N Engl J Med* 2005;**353**:2550–8. doi:10.1056/NEJMoa051135
- 545 24 Isenberg DA, Rahman A, Allen E, *et al.* BILAG 2004. Development and initial
546 validation of an updated version of the British Isles Lupus Assessment Group’s disease
547 activity index for patients with systemic lupus erythematosus. *Rheumatology (Oxford)*
548 2005;**44**:902–6. doi:10.1093/rheumatology/keh624
- 549 25 Gordon C, Sutcliffe N, Skan J, *et al.* Definition and treatment of lupus flares measured
550 by the BILAG index. *Rheumatology (Oxford)* 2003;**42**:1372–9.
551 doi:10.1093/rheumatology/keg382
- 552 26 Isenberg DA, Allen E, Farewell V, *et al.* An assessment of disease flare in patients
553 with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of
554 SELENA. *Ann Rheum Dis* 2011;**70**:54–9. doi:10.1136/ard.2010.132068
- 555 27 Mathian A, Mouries-Martin S, Dorgham K, *et al.* Monitoring Disease Activity in
556 Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked
557 Immunosorbent Assay Quantification of Serum Interferon- α . *Arthritis Rheumatol*
558 2019;**71**:756–65. doi:10.1002/art.40792
- 559 28 Sterlin D, Mathian A, Miyara M, *et al.* IgA dominates the early neutralizing antibody
560 response to SARS-CoV-2. *Sci Transl Med* 2021;**13**. doi:10.1126/scitranslmed.abd2223
- 561 29 Sahin U, Muik A, Derhovanessian E, *et al.* COVID-19 vaccine BNT162b1 elicits
562 human antibody and T(H)1 T cell responses. *Nature* 2020;**586**:594–9. doi:10.1038/s41586-
563 020-2814-7

- 564 30 Liu J, Liu Y, Xia H, *et al.* BNT162b2-elicited neutralization of B.1.617 and other
565 SARS-CoV-2 variants. *Nature* Published Online First: 10 June 2021. doi:10.1038/s41586-
566 021-03693-y
- 567 31 Planas D, Veyer D, Baidaliuk A, *et al.* Reduced sensitivity of infectious SARS-CoV-2
568 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated
569 individuals. *bioRxiv* 2021;:2021.05.26.445838. doi:10.1101/2021.05.26.445838
- 570 32 Ferreira I, Datir R, Papa G, *et al.* SARS-CoV-2 B.1.617 emergence and sensitivity to
571 vaccine-elicited antibodies. *bioRxiv* 2021;:2021.05.08.443253.
572 doi:10.1101/2021.05.08.443253
- 573 33 Campochiaro C, Trignani G, Tomelleri A, *et al.* Potential acceptance of COVID-19
574 vaccine in rheumatological patients: a monocentric comparative survey. *Ann Rheum Dis*
575 Published Online First: 28 January 2021. doi:10.1136/annrheumdis-2020-219811
- 576 34 Pugès M, Biscay P, Barnetche T, *et al.* Immunogenicity and impact on disease activity
577 of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic
578 literature review and meta-analysis. *Rheumatology (Oxford)* 2016;**55**:1664–72.
579 doi:10.1093/rheumatology/kew211
- 580 35 Boyarsky BJ, Werbel WA, Avery RK, *et al.* Immunogenicity of a Single Dose of
581 SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. *JAMA*
582 2021;**325**:1784–6. doi:10.1001/jama.2021.4385
- 583 36 Haberman RH, Herati R, Simon D, *et al.* Methotrexate hampers immunogenicity to
584 BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. *Ann*
585 *Rheum Dis* Published Online First: 25 May 2021. doi:10.1136/annrheumdis-2021-220597
- 586 37 Kapetanovic MC, Nagel J, Nordström I, *et al.* Methotrexate reduces vaccine-specific

587 immunoglobulin levels but not numbers of circulating antibody-producing B cells in
588 rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. *Vaccine*
589 2017;**35**:903–8. doi:10.1016/j.vaccine.2016.12.068

590 38 Kapetanovic MC, Roseman C, Jönsson G, *et al.* Antibody response is reduced
591 following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-
592 treated patients with established arthritis, but not those treated with tumor necrosis factor
593 inhibitors. *Arthritis Rheum* 2011;**63**:3723–32. doi:10.1002/art.30580

594 39 Park JK, Lee MA, Lee EY, *et al.* Effect of methotrexate discontinuation on efficacy of
595 seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical
596 trial. *Ann Rheum Dis* 2017;**76**:1559–65. doi:10.1136/annrheumdis-2017-211128

597 40 Park JK, Lee YJ, Shin K, *et al.* Impact of temporary methotrexate discontinuation for
598 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid
599 arthritis: a randomised clinical trial. *Ann Rheum Dis* 2018;**77**:898–904.
600 doi:10.1136/annrheumdis-2018-213222

601 41 Park JK, Kim MJ, Choi Y, *et al.* Effect of short-term methotrexate discontinuation on
602 rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials. *Clin*
603 *Rheumatol* 2020;**39**:375–9. doi:10.1007/s10067-019-04857-y

604 42 Park JK, Choi Y, Winthrop KL, *et al.* Optimal time between the last methotrexate
605 administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of
606 a randomised clinical trial. *Ann Rheum Dis* 2019;**78**:1283–4. doi:10.1136/annrheumdis-2019-
607 215187

608 43 Rabinowich L, Grupper A, Baruch R, *et al.* Low immunogenicity to SARS-CoV-2
609 vaccination among liver transplant recipients. *J Hepatol* Published Online First: 21 April
610 2021. doi:10.1016/j.jhep.2021.04.020

- 611 44 Ruddy JA, Connolly CM, Boyarsky BJ, *et al.* High antibody response to two-dose
612 SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal
613 diseases. *Ann Rheum Dis* Published Online First: 24 May 2021. doi:10.1136/annrheumdis-
614 2021-220656
- 615 45 Herishanu Y, Avivi I, Aharon A, *et al.* Efficacy of the BNT162b2 mRNA COVID-19
616 vaccine in patients with chronic lymphocytic leukemia. *Blood* 2021;**137**:3165–73.
617 doi:10.1182/blood.2021011568
- 618 46 Odendahl M, Jacobi A, Hansen A, *et al.* Disturbed peripheral B lymphocyte
619 homeostasis in systemic lupus erythematosus. *J Immunol* 2000;**165**:5970–9.
620 doi:10.4049/jimmunol.165.10.5970
- 621 47 Dörner T, Jacobi AM, Lee J, *et al.* Abnormalities of B cell subsets in patients with
622 systemic lupus erythematosus. *J Immunol Methods* 2011;**363**:187–97.
623 doi:10.1016/j.jim.2010.06.009
- 624 48 Kreer C, Zehner M, Weber T, *et al.* Longitudinal Isolation of Potent Near-Germline
625 SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. *Cell* 2020;**182**:843-854.e12.
626 doi:10.1016/j.cell.2020.06.044
- 627 49 Feldman J, Bals J, Denis KSt, *et al.* Naive human B cells can neutralize SARS-CoV-2
628 through recognition of its receptor binding domain. *bioRxiv* 2021;:2021.02.02.429458.
629 doi:10.1101/2021.02.02.429458
- 630 50 Rincon-Arevalo H, Choi M, Stefanski A-L, *et al.* Impaired humoral immunity to
631 SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. *Sci*
632 *Immunol* 2021;**6**. doi:10.1126/sciimmunol.abj1031
- 633 51 Van Praet JT, Vandecasteele S, De Roo A, *et al.* Humoral and cellular

634 immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in nursing home residents. *Clin*
635 *Infect Dis* Published Online First: 7 April 2021. doi:10.1093/cid/ciab300

636 52 Zuo J, Dowell AC, Pearce H, *et al.* Robust SARS-CoV-2-specific T cell immunity is
637 maintained at 6 months following primary infection. *Nat Immunol* 2021;**22**:620–6.
638 doi:10.1038/s41590-021-00902-8

639 53 Khoury DS, Cromer D, Reynaldi A, *et al.* Neutralizing antibody levels are highly
640 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*
641 Published Online First: 17 May 2021. doi:10.1038/s41591-021-01377-8

642 54 D’Silva KM, Serling-Boyd N, Hsu TY-T, *et al.* SARS-CoV-2 antibody response after
643 COVID-19 in patients with rheumatic disease. *Ann Rheum Dis* Published Online First: 12
644 January 2021. doi:10.1136/annrheumdis-2020-219808

645

646

647

648

649 **Figure 1. Study population and enrollment process.**

650 SLE patients were offered BNT162b2 vaccine through January 15, 2021.

651

652 **Figure 2. Evolution of SLE activity following vaccination**

653 A. Repartition of maximal BILAG score at baseline and following vaccination

654 B. Evolution of mean SLEDAI 2K score following vaccination

655

656 **Figure 3: Vaccine-induced neutralizing potency**

657 A. Comparison of serum anti-RBD IgG levels measured by photonic ring
658 immunoassay with neutralizing capacity against D614G SARS-CoV-2 (n=126).
659 Spearman coefficient (r) and p value (p) are indicated.

660 B. Serum neutralizing activities against D614G SARS-CoV-2 measured as ID50 in
661 126 serum samples at D42. MTX- and MMF-treated patients are colour-coded
662 (blue and red, respectively). Patients receiving other treatments are indicated in
663 black. The boxplots show medians (middle line) and first and third quartiles while
664 the whiskers indicate minimal and maximal values. P value was calculated using
665 Kruskal-Wallis test (* p<0.05).

666 C. Comparison of serum neutralizing activities measured as ID50s against D614G
667 SARS-CoV-2 in SLE patients with baseline low (grey, n=19) or high (black, n=40)
668 naïve B cell frequency (arbitrary cut-off=42% of total B cells). Naïve B cells (N)
669 are defined as CD27-Ig⁺ B cells, switched memory B cells (S) as CD27-IgD⁻,
670 marginal zone B cells (M) as CD27-IgD⁺ and double negative B cells (DN) as
671 CD27-IgD⁻. The boxplots show medians (middle line) and first and third quartiles

672 while the whiskers indicate minimal and maximal values. P value was calculated
673 using Mann-Whitney test (* $p < 0.05$).

674 D. Serum neutralizing activities against D614G SARS-CoV-2 measured as ID50 in 59
675 SLE patients classified according to their naive B cells counts. Q1, Q2, Q3 and Q4
676 defined the naive B cell count quartiles. P value was calculated using Kruskal-
677 Wallis test (* $p < 0.05$; *** $p < 0.001$).

678 E. Serum neutralizing activities against indicated SARS-CoV-2 variants B.1.1.7
679 (Alpha), B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3, B.1.28 (Gamma), and
680 B.1.351 (Beta) measured as ID50 in 46 serum samples at D42. The boxplots show
681 medians (middle line) and first and third quartiles while the whiskers indicate
682 minimal and maximal values. P value was calculated using Kruskal-Wallis test
683 (** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$).

684 F. Positive rates of serum neutralizing activity against SARS-CoV-2 variants in 46
685 SLE samples at day 42. Patient were defined as “neutralizers” (black) or “non-
686 neutralizers” (grey) according to presence of neutralizing activity at first serum
687 dilution (1/30), or not.

688 **Figure 4: T-cell responses correlate with anti-SARS-CoV-2 humoral responses**

689 A. Positives rates of Quantiferon SARS-CoV-2 testing in 40 SLE patients at D42,
690 grouped according to serum neutralizer and non neutralizer status, as defined in Figure
691 3D. Numbers indicate the percentage of patients with a detectable T cell response.

692 B. Comparison of $IFN\gamma$ levels (UI/ml) after specific T cell stimulation using Quantiferon
693 SARS-CoV-2 test and serum neutralizing activity reported with ID50 in 40 SLE
694 patients at D45. Spearman coefficient (r) and p value (p) are indicated.

695

Figure 1




Figure 2





Figure 3




Figure 4

